Cancer Res: The Causes of Chemotherapy Resistance in Breast Cancer

June 26, 2019NewsBreast Cancer, Chemotherapy Resistancebiorab

According to a study recently published in Cancer Research by researchers and colleagues at the Belvich Institute of Biomedicine at the University of Barcelona, a large number of replicated chromosome regions areRead More…

Scientists Found that Potassium Ions are the Key to Controlling the Anticancer Ability of T cells

April 17, 2019NewsCancer, Potassium Ion, T cellbiorab

A study led by scientists at the Center for Cancer Research (CCR) at the American National Cancer Institute (NCI) has revealed a way to promote the continued growth of tumors in theRead More…

3D Bio-printing Model Changes Anti-cancer Drug Development and Anti-tumor Therapy

February 19, 2019News3D Model, Bio-printing, Cancerbiorab

Researchers at the University of Minnesota have developed a way to study cancer cells, which could lead to new and more effective treatments. They have developed a new method to study theseRead More…

Nine characteristics shared by the most successful mAb

February 1, 2019News, Therapeutic Antibody R&Dantibody discovery, monoclonal antibody drug, therapeutic antibodybiorab

The path to finding a therapeutic antibody that leads to significant medical improvements is often complicated, long, and costly. Many criteria have to be taken into account in order to begin theRead More…

Sixteen New Tumor Drugs First Approved in 2018

December 28, 2018News, Therapeutic Antibody R&Dantibody discovery, therapeutic antibodybiorab

In 2018, from the approval of JNJ’s apalutamide in the United States on February 14 to that of larotrectinib on November 26, a total of 16 new tumor drugs were approved forRead More…

Nat Genet：Scientists Discover New Target for Immunotherapy Following 2018 Nobel Prize for Medicine

December 20, 2018News, Therapeutic Antibody R&Dantibody discovery, immunotherapy, monoclonal antibody drug, therapeutic antibodybiorab

Following the 2018 Nobel Prize for Medicine, global attention is now more than ever turned toward the promise of immunotherapy in oncology. According to a recent study published in the international journalRead More…

The First Rituxan Biosimilar Is Expected to Be Approved by FDA

October 25, 2018News, Therapeutic Antibody R&Dantibody discovery, monoclonal antibody drug, Rituximab, therapeutic antibodybiorab

B cell lymphoma is a solid tumor that occurs in B cells, including Hodgkin’s lymphoma and non-Hodgkin’s lymphoma. In numerous types of B cell lymphoma, classic Hodgkin’s lymphoma and nodular lymphocyte areRead More…

First Approval for Fremanezumab-vfrm

September 27, 2018News, Therapeutic Antibody R&Dantibody discovery, monoclonal antibody, monoclonal antibody drug, therapeutic antibodybiorab

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AJOVYTM (fremanezumab-vfrm) injection for the preventive treatment of migraine in adults. AJOVY, aRead More…

Antibody Combo Knocks Down HIV in Clinical Trials

September 27, 2018News, Therapeutic Antibody R&Dantibody combination, blocking antibody, hiv immunology, monoclonal antibody, monoclonal antibody drug, therapeutic antibodybiorab

A mix of two monoclonal antibodies against HIV tamped down virus levels in patients not taking antiretroviral medication, according to the results of two early-stage clinical trials reported in nature. After several infusionsRead More…

The First Single Domain Antibody (sdAb) Drug Was Approved by EMA

September 6, 2018Antibody Engineering R&D, Newscaplacizumab, single domain antibody (sdAb)biorab

On September 3, 2018, the EMA approved the single domain antibody (sdAb) drug Cablivi (Caplacizumab) in Sanofi for the treatment of adult-acquired Thrombotic Thrombocytopenic Purpura (aTTP). Cablivi became the first specific aTTPRead More…